Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Fundamental Home Items Each Animal person Needs - 2Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- 3Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- 4A Past filled with Old Civilizations: The World's Most established Societies
- 5See the moon shine with Saturn in the southern sky after sunset Dec. 26
- The Solution to Ecological Protection: Saving Nature for People in the future
- Antivirus Programming for Exhaustive Security
- 7 Popular Vacation destinations In China
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- Top Music and Dance Celebration: Which One Gets You Going?
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Pick Your Number one Sort Of Music
- Astronauts' brains change shape and position after time in space, study finds
